@article { author = {}, title = {Clinical Observations on Safety of Fixed Dose Rate GemcitabineChemotherapy by Intravenous Infusion}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {11}, number = {2}, pages = {553-555}, year = {2010}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {Purpose: To observe the safety of fixed dose rate gemcitabine by intravenous infusion (iv-FDR) for cancers.Methods: From January 1, 2007 to December 31, 2009, four patients who were pathologically diagnosed withadvanced pancreatic or breast cancer were recruited into this study. They were treated by gemcitabine 10mg/m2/min iv-FDR on days 1 and 8, and combined with other chemotherapeutics, repeated every four weeks. Toxicitywas determined in line with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC). Results:The main toxicity was reversible myelosuppression; other side effects included gastrointestinal toxicity andliver impairment. Cardiac or renal toxicity was not detected. Conclusion: The toxicity of iv-FDR gemcitabinecombination chemotherapy was well tolerated, so that iv-FDR gemcitabine deserves to be further studied as atreatment option.}, keywords = {Gemcitabine,fixed dose rate,Chemotherapy,Toxicity}, url = {https://journal.waocp.org/article_25238.html}, eprint = {https://journal.waocp.org/article_25238_2d5bbe8807e170aa6a717ed841cb3e0e.pdf} }